Floxsafe/Floxsafe IV Indications/Uses

Floxsafe: Moxifloxacin 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to moxifloxacin. Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed: Acute bacterial sinusitis (adequately diagnosed).
Acute exacerbations of chronic bronchitis (adequately diagnosed).
Community acquired pneumonia, except severe cases.
Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess.
Moxifloxacin 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing moxifloxacin resistance of Neisseria gonorrhoeae unless moxifloxacin-resistant Neisseria gonorrhoeae can be excluded.
Moxifloxacin 400 mg film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous moxifloxacin for the following indications: Community acquired pneumonia; Complicated skin and skin structure infections.
Moxifloxacin 400 mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection or in severe community acquired pneumonia.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Floxsafe IV: Susceptible strains.
Gram-positive microorganisms: Enterococcus faecalis (many strains only moderately susceptible), Staphylococcus aureus (including methicillin-susceptible isolates), Streptococcus milleri group (Streptococcus anginosus, Streptococcus constellatus), Streptococcus pneumonia (including Penicillin and Macrolide resistant isolates), Streptococcus pyogenes (A group), Streptococcus mitior, Streptococcus agalactiae, Streptococcus dysgalactiae, Staphylococcus cohnii, Staphylococcus epidermidis (including methicillin-susceptible isolates), Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, Staphylococcus simulans.
Gram-negative microorganisms: Haemophilus influenzae (includuing β-lactamase negative and positive strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including β-lactamase negative and positive strains), E. coli, Enterobacter cloacae, Bordetella pertussis, Klebsiella oxytoca, Enterobacteraerogenes, Enterobacter intermedius, Enterobacter sakazaki, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia rettgeri.
Heterologous: Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, Coxiella burnettii.
Anaerobes: Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Fusobacterium spp., Porphyromonas spp., Porphyromonas anaerobius, Porphyromonas asaccharolyticus, Porphyromonas magnus, Prevotella spp., Clostridium perfringens, Peptostreptococcus species.
Respiratory infections: Acute sinusitis, Acute Exacerbation of Chronic Bronchitis, Pneumonia.
Skin and Skin Structure Infections.
Complicated Intra-Abdominal Infections.